<bill session="115" type="h" number="4724" updated="2023-01-11T13:39:12Z">
  <state datetime="2017-12-21">REFERRED</state>
  <status>
    <introduced datetime="2017-12-21"/>
  </status>
  <introduced datetime="2017-12-21"/>
  <titles>
    <title type="display">Medicare IVIG Access Enhancement Act</title>
    <title type="official" as="introduced">To provide for a demonstration project to further examine the benefits of providing coverage and payment for items and services necessary to administer intravenous immune globulin (IVIG) in the home, and for other purposes.</title>
    <title type="short" as="introduced">Medicare IVIG Access Enhancement Act</title>
  </titles>
  <sponsor bioguide_id="H001065"/>
  <cosponsors>
    <cosponsor bioguide_id="B001273" joined="2018-05-15"/>
    <cosponsor bioguide_id="B000574" joined="2017-12-21"/>
    <cosponsor bioguide_id="B001285" joined="2018-09-07"/>
    <cosponsor bioguide_id="B001251" joined="2017-12-21"/>
    <cosponsor bioguide_id="C001072" joined="2018-08-10"/>
    <cosponsor bioguide_id="C001106" joined="2018-02-20"/>
    <cosponsor bioguide_id="C001063" joined="2018-04-24"/>
    <cosponsor bioguide_id="D000399" joined="2018-04-05"/>
    <cosponsor bioguide_id="G000559" joined="2018-01-30"/>
    <cosponsor bioguide_id="K000376" joined="2018-03-01"/>
    <cosponsor bioguide_id="L000567" joined="2017-12-21"/>
    <cosponsor bioguide_id="M001163" joined="2018-06-26"/>
    <cosponsor bioguide_id="M001181" joined="2017-12-21"/>
    <cosponsor bioguide_id="R000435" joined="2018-10-16"/>
  </cosponsors>
  <actions>
    <action datetime="2017-12-21">
      <text>Introduced in House</text>
    </action>
    <action datetime="2017-12-21" state="REFERRED">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2017-12-21">
      <text>Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.</text>
    </action>
    <action datetime="2017-12-22">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
    <committee code="HSWM" name="House Ways and Means" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Congressional oversight"/>
    <term name="Drug therapy"/>
    <term name="Government studies and investigations"/>
    <term name="Health care costs and insurance"/>
    <term name="Health care coverage and access"/>
    <term name="Home and outpatient care"/>
    <term name="Medicare"/>
    <term name="Neurological disorders"/>
  </subjects>
  <amendments/>
  <summary date="2018-06-27T12:57:39Z" status="Introduced in House">Medicare IVIG Access Enhancement Act

This bill requires the Centers for Medicare &amp; Medicaid Services to establish a three-year demonstration project to evaluate the benefits of providing Medicare coverage and payment for items and services needed for the in-home administration of intravenous immune globulin to treat chronic inflammatory demyelinating polyneuropathy or multifocal motor neuropathy. Beneficiary participation shall be voluntary.</summary>
</bill>
